Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients: A Real-World evidence in the Indian Population
Brain Research · 2026-04 · 1877-1878 · 150205
DOI: 10.1016/j.brainres.2026.150205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2026-04. Verfasst von Anuj Kumar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, 410210. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, DNA Modification Methylases, DNA Repair Enzymes, Tumor Suppressor Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
IDH-mutant (IDHmt) high-grade gliomas (HGG) differ significantly from IDH-wildtype (IDHwt) HGG, or glioblastoma (GBM). MGMT promoter methylation (MGMTp) is an established prognostic marker in GBM, but its role in IDHmt HGG remains unclear. We evaluated the prognostic impact of IDH mutation and MGMTp in 395 uniformly treated HGG patients in India. All patients underwent maximal safe resection followed by adjuvant radiotherapy and concurrent plus maintenance temozolomide (TMZ). MGMTp was assessed by methylation-specific PCR, and IDH1/2 mutations by immunohistochemistry and targeted sequencing. Median age was 50 years; median follow-up was 63 months. IDH mutations were present in 15.4 % of patients, and MGMTp in 36.7 %. Median overall survival (OS) was 19 months; 2-year OS was 41.5 %. Age > 50 years (HR 1.77, p < 0.001),
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, 410210.
- Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, 400012.
- Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, 400012.
- Department of Neurosurgery, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, 410210.
- Department of Neurosurgery, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, 400012.
- Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, 410210. Electronic address: godajayantsastri@gmail.com.
Zitieren
APA
Kumar, A., Gurav, M., Sarkar, J., Bapat, P., Madhu, K., Shetty, O., Chatterjee, A., Sahay, A., Dasgupta, A., Moiyadi, A., Shetty, P., Gupta, T., Goda, J. S., & Epari, S. (2026). Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients: A Real-World evidence in the Indian Population. Brain Research, 1877-1878, 150205. https://doi.org/10.1016/j.brainres.2026.150205
Vancouver
Kumar A, Gurav M, Sarkar J, Bapat P, Madhu K, Shetty O, et al. Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients: A Real-World evidence in the Indian Population. Brain Research. 2026;1877-1878:150205. doi:10.1016/j.brainres.2026.150205
BibTeX
@article{Kumar2026,
author = {Kumar, Anuj and Gurav, Mamta and Sarkar, Joyita and Bapat, Prachi and Madhu, Kalyani and Shetty, Omshree and Chatterjee, Abhishek and Sahay, Ayushi and Dasgupta, Archya and Moiyadi, Aliasgar and Shetty, Prakash and Gupta, Tejpal and Goda, Jayant S and Epari, Sridhar},
title = {Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients: A Real-World evidence in the Indian Population},
journal = {Brain Research},
year = {2026},
volume = {1877-1878},
pages = {150205},
doi = {10.1016/j.brainres.2026.150205}
}
EUVIMED